Chronic Wounds: Bedsores – Diabetic ulcers – Surgical injuries

Chronic wounds & bedsores


A chronic wound develops when any acute wound fails to heal in the expected time frame for that type of wound, which might be a couple of weeks or up to six weeks in some cases. Failure of any wound to heal can be due to a lack of one or more of the main requirements of healing, including a good supply of blood, oxygen and nutrients, and a clean and infection-free environment. 

Bedsore / Pressure ulcer: The constant pressure and friction resulting from body weight over a localized area for prolonged duration can lead to breakage of skin and ulceration (also known as bed sores); especially on the back and on the ankles and feet.



Diabetes is the pathology that causes the most ulcers, it causes neuropathic and pressure ulcers which corresponds to 80% of the ulcers! According to World Health Organization more that 50% of diabetic’s patients suffer from ulcers.

Ideal Treatment Approach:

Our body’s natural physiology is programmed to heal any damage or injury immediately. Any wound can heal within a few days if the basic conditions essential for life and cell growth are provided. Therefore, an ideal treatment should just create a favorable environment for cell growth. The wound will heal if cells can grow.


Filmogen liquid bandage for the treatment of superficial bedsores and chronic wounds.

Currently Available Treatments:     

In spite of the last decades’ continuous research, there is currently no truly efficient cell growth-promoting treatment for chronic wounds. Almost all existing treatments only partially provide the conditions necessary for cell growth. Most are designed to keep the wound surface hydrated, to minimize pain, and reduce the contaminant load, but none is intended to directly stimulate cell growth. Treatment with ECM components such as hyaluronic acid and collagen, or whole intestinal ECM, never produced satisfactory results because the composition of naturally secreted ECM is very complex, cell-specific, and practically impossible to reproduce artificially by mixing individual ECM components.

Except for some encouraging in vitro results, which have led to the development of collagen-based wound dressings aiming at broad spectrum MMP modulation, there is currently no truly promising treatment designed to selectively target and reduce the amount of ECM-damaging MMPs on the wound surface.

Currently, chronic wounds (bedsores, diabetic ulcers, venous leg ulcers) are treated with saline solution (to clean & hydrate), antiseptics & antibiotics (to reduce infection), hydrocolloid dressings (to hydrate), absorbent hydrogels & alginates (to remove excessive exudates), bio-membranes (as skin grafts), ECM substitutes (to supply Extra Cellular Matrix components), silver nitrate (to cauterize), surgical methods (to remove dead and dry tissue), negative pressure therapy (to reduce MMP concentration & to improve circulation) and growth factors (to stimulate cell growth & healing).

VITROBIO’s NEW Therapeutic Approach:

Vitrobio invented and patented an osmotically active, hypertonic, antiseptic but cell friendly solution for topical application. The solution was further rendered filmogen for a long-lasting adherence on the biological surfaces. When sprayed on the tissue surface, the film instantly attracts hypotonic liquid from the inner parts of the tissue, keeping the surface permanently hydrated. The osmotic liquid flow equally detaches & drains all the contaminants (including microorganisms, free virus particles, cell debris, protein molecules) from the surface. When the surface is clean, healing starts immediately. When applied on a wound surface, the film does not allow microbial growth, keeps the wound hydrated and contaminant free which in turn facilitates healing.  (For detailed mode of action: please contact Vitrobio)

Product Presentation: 50 ml tube fitted with a canula

Directions: Wash hands. Clean the wound surface with a cotton gauze soaked in physiological saline or a gentle wound cleanser. According to the size of the injury, pour a sufficient amount of AS-22 solution directly onto the wound so as to form a thin film over the entire surface. We suggest protecting the wound by covering it with a clean and breathable cotton gauze bandage allowing aeration. Wipe the tip of the tube with a clean tissue after use. Close the tube with the plastic cover after each use. For young patients, product should be applied by an adult or at least with adult supervision and/or assistance. 

When beginning the treatment, apply twice a day for non-exuding wounds or 3-4 times a day for exuding wounds. Then at least once a day. Interrupt the treatment for at least 2 days after each period of 30 consecutive days of use.

Contraindications: Check the product’s composition and do not use if you are sensitive or allergic to any of the ingredients. Although all the ingredients used to prepare this product are derived from food ingredients and used in very small quantities, in the absence of sufficient specific safety data, do not use this product during pregnancy or breastfeeding without medical advice and in children below the age of 12

Side EffectsIn certain cases, a slight to moderate local irritation may be observed following application but will disappear after a few minutes. If you observe any type of allergic reaction after product application (ex: strong persistent irritation/ burning sensation), cease using the product, flush the wound surface thoroughly with clear fresh water, and consult a medical professional if necessary. If you notice any serious incidents due to the use of this product, please notify immediately the manufacturer/distributor and national competent authorities.

Clinical Efficacy:

Full trial published in Dove Press Journal: Chronic Wound Care Management and Research, 2014: A new generation of topical chronic wound treatments containing specific MMP inhibitors